Maximizing patient safety when prescribing opioids for pain management

Megan Judy; David Sams; Stephon Poulton

doi:10.1097/01.JAA.0000947084.60262.4e

Maximizing patient safety when prescribing opioids for pain management

JAAPA. 2023 Sep 1;36(9):1-6. doi: 10.1097/01.JAA.0000947084.60262.4e.

Authors

Megan Judy¹, David Sams, Stephon Poulton

Affiliation

¹ Megan Judy practices in general surgery in Greensburg, Pa. David Sams is an assistant professor in the PA program at Marietta College and practices at OhioHealth CampusCare in Athens, Ohio. Stephon Poulton is an adjunct professor in the PA program at Marietta College and a clinical pharmacist with Genesis Healthcare Systems in Zanesville, Ohio. The authors have disclosed no potential conflicts of interest, financial or otherwise.

PMID: 37668489
DOI: 10.1097/01.JAA.0000947084.60262.4e

Abstract

Cytochrome P450 enzyme metabolism is altered by environmental and genetic factors, which can affect the efficacy and safety of opioids. This article describes CYP polymorphisms and how pharmacogenetic testing could be used to help clinicians make safer decisions about opioid use in patients.

MeSH terms

Analgesics, Opioid* / adverse effects
Humans
Opioid-Related Disorders* / prevention & control
Pain Management
Patient Safety
Pharmacogenomic Testing

Substances

Analgesics, Opioid